ATE179613T1 - Verhütung und behandlung von zytomegalovirus mittels aminopeptidase - Google Patents

Verhütung und behandlung von zytomegalovirus mittels aminopeptidase

Info

Publication number
ATE179613T1
ATE179613T1 AT94906142T AT94906142T ATE179613T1 AT E179613 T1 ATE179613 T1 AT E179613T1 AT 94906142 T AT94906142 T AT 94906142T AT 94906142 T AT94906142 T AT 94906142T AT E179613 T1 ATE179613 T1 AT E179613T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
cytomegalovirus
aminoopeptidase
aminopeptidases
Prior art date
Application number
AT94906142T
Other languages
English (en)
Inventor
John A Zaia
Terrence Giugni
Erna Moeller
Cecilia Soederberg
Original Assignee
Erna Moeller
Cecilia Soederberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erna Moeller, Cecilia Soederberg filed Critical Erna Moeller
Application granted granted Critical
Publication of ATE179613T1 publication Critical patent/ATE179613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT94906142T 1993-01-21 1994-01-21 Verhütung und behandlung von zytomegalovirus mittels aminopeptidase ATE179613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US698293A 1993-01-21 1993-01-21
US9966493A 1993-07-30 1993-07-30

Publications (1)

Publication Number Publication Date
ATE179613T1 true ATE179613T1 (de) 1999-05-15

Family

ID=26676317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94906142T ATE179613T1 (de) 1993-01-21 1994-01-21 Verhütung und behandlung von zytomegalovirus mittels aminopeptidase

Country Status (11)

Country Link
US (1) US6511662B1 (de)
EP (1) EP0680333B1 (de)
JP (1) JPH08506106A (de)
AT (1) ATE179613T1 (de)
AU (1) AU681115B2 (de)
CA (1) CA2154346A1 (de)
DE (1) DE69418307T2 (de)
DK (1) DK0680333T3 (de)
ES (1) ES2131188T3 (de)
GR (1) GR3030462T3 (de)
WO (1) WO1994016724A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527489A (ja) * 1998-10-22 2002-08-27 キュラゲン コーポレイション 腎疾患および関連疾患に対する予想および治療的遺伝子およびタンパク質
RU2272645C2 (ru) * 2004-01-19 2006-03-27 Светлана Николаевна Козлова Способ лечения цмв-инфекции у детей раннего возраста
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF

Also Published As

Publication number Publication date
DK0680333T3 (da) 2000-01-03
EP0680333B1 (de) 1999-05-06
DE69418307T2 (de) 1999-11-04
AU681115B2 (en) 1997-08-21
AU5999194A (en) 1994-08-15
CA2154346A1 (en) 1994-08-04
DE69418307D1 (de) 1999-06-10
EP0680333A1 (de) 1995-11-08
JPH08506106A (ja) 1996-07-02
GR3030462T3 (en) 1999-10-29
ES2131188T3 (es) 1999-07-16
US6511662B1 (en) 2003-01-28
WO1994016724A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
BG100455A (en) Hiv protease inhibitors
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
ATE438397T1 (de) Pharmazeutische zubereitung enthaltend pioglitazone und glimepiride zur verwendung in der behandlung von diabetes
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
DE3750934D1 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE179613T1 (de) Verhütung und behandlung von zytomegalovirus mittels aminopeptidase
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
DE69522685D1 (de) Behandlung von blut-plasma
DE3874606D1 (de) Behandlung von viraler infektion.
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
ATE229343T1 (de) Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee